The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up ...

Researchers in Europe have called for action to safeguard the independence of patient organisations, after finding potential for a "hidden conflict of interest" in a study. The team from the ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

Every day, thousands worldwide find out they have a disease or health condition that requires care. And each day more and more people don’t get the care they need because they don’t understand ...

Chipmaker Advanced Micro Devices (AMD) has followed in the footsteps of its arch-rival NVIDIA and started to build a presence in artificial intelligence-powered drug discovery – starting with a ...

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...

Healthcare is transitioning to a patient-centric approach and healthcare consumerism. Patients have fast become consumers first, with the freedom to make decisions about their health journeys, and ...

The FDA has responded to the increasing use of artificial intelligence (AI) in the discovery and development of drugs and biologics by publishing its first provisional guidance on the technology's ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

The recent launch of SearchGPT by OpenAI marks the beginning of a significant shift in how information is searched and consumed for pharma and healthcare industry leaders. Unlike traditional ...

Pharmacy closures are accelerating fast. Pharmacy numbers dropped from 11,522 in 2022 to 11,414 in 2023, and a further 436 closed this year in 2024. As numbers dwindle, it shouldn’t come as much ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.